Allstate Cut Abbott Labs (ABT) Position By $1.18 Million; 11 Analysts Covering Acuity Brands, Inc. (AYI)

November 8, 2017 - By wolcottdaily

Allstate Corp decreased Abbott Labs (ABT) stake by 40.61% reported in 2017Q2 SEC filing. Allstate Corp sold 24,663 shares as Abbott Labs (ABT)’s stock declined 3.42%. The Allstate Corp holds 36,061 shares with $1.75 million value, down from 60,724 last quarter. Abbott Labs now has $96.17 billion valuation. The stock increased 0.16% or $0.09 on November 8, reaching $55.25. About 2.84 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since November 8, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Among 20 analysts covering Acuity Brands Inc. (NYSE:AYI), 11 have Buy rating, 2 Sell and 7 Hold. Therefore 55% are positive. Acuity Brands Inc. had 50 analyst reports since August 21, 2015 according to SRatingsIntel. JMP Securities initiated Acuity Brands, Inc. (NYSE:AYI) rating on Thursday, December 8. JMP Securities has “Mkt Underperform” rating and $200 target. The firm has “Neutral” rating given on Tuesday, December 20 by Robert W. Baird. CLSA downgraded Acuity Brands, Inc. (NYSE:AYI) on Thursday, April 7 to “Outperform” rating. The stock has “Buy” rating by Canaccord Genuity on Monday, January 11. Roth Capital maintained Acuity Brands, Inc. (NYSE:AYI) rating on Monday, April 3. Roth Capital has “Sell” rating and $150 target. Robert W. Baird downgraded the stock to “Neutral” rating in Tuesday, September 19 report. As per Thursday, October 6, the company rating was upgraded by Canaccord Genuity. The rating was initiated by Credit Agricole with “Buy” on Thursday, February 25. The firm earned “Outperform” rating on Tuesday, January 10 by Robert W. Baird. Oppenheimer maintained the stock with “Outperform” rating in Friday, February 12 report. See Acuity Brands, Inc. (NYSE:AYI) latest ratings:

13/10/2017 Broker: KeyBanc Capital Markets Rating: Sector Weight Initiates Coverage On
04/10/2017 Broker: Cowen & Co Rating: Buy New Target: $219.0 Maintain
03/10/2017 Broker: JMP Securities Old Rating: Market Underperform New Rating: Market Perform Old Target: $183 Upgrade
22/09/2017 Broker: Cowen & Co Rating: Buy New Target: $222.0 Maintain
19/09/2017 Broker: Robert W. Baird Old Rating: Outperform New Rating: Neutral Downgrade
15/09/2017 Broker: Wells Fargo Rating: Hold Downgrade
05/09/2017 Broker: Robert W. Baird Rating: Buy New Target: $212.0 Maintain
01/09/2017 Broker: Cowen & Co Rating: Buy New Target: $226.0 Maintain
24/08/2017 Broker: Oppenheimer Rating: Buy New Target: $230.0 Maintain
16/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $215.0 Maintain

Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.75, from 1.63 in 2017Q1. It turned negative, as 69 investors sold ABT shares while 545 reduced holdings. 102 funds opened positions while 441 raised stakes. 1.22 billion shares or 0.83% more from 1.21 billion shares in 2017Q1 were reported. Mitsubishi Ufj And Bk stated it has 0.34% of its portfolio in Abbott Laboratories (NYSE:ABT). Peak Asset Management Limited Liability accumulated 18,345 shares or 0.33% of the stock. 18,720 were accumulated by Washington Cap Management. 9,563 are held by Eqis Mgmt. Koshinski Asset Mgmt invested in 0% or 8,124 shares. Chemical State Bank invested in 0.83% or 156,493 shares. Thomaspartners Incorporated stated it has 4.89 million shares. Dalton Greiner Hartman Maher And invested in 0.96% or 340,629 shares. Granite Investment Ptnrs Limited Liability Co has invested 0.17% in Abbott Laboratories (NYSE:ABT). Silvercrest Asset Group Limited Liability Company invested 1.25% in Abbott Laboratories (NYSE:ABT). Paw owns 14,000 shares. Hbk Sorce Advisory Ltd has 11,341 shares for 0.09% of their portfolio. Grassi Investment reported 111,310 shares or 0.95% of all its holdings. Kidder Stephen W reported 137,509 shares. Finemark Commercial Bank owns 102,487 shares or 0.36% of their US portfolio.

Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Abbott Laboratories had 87 analyst reports since July 24, 2015 according to SRatingsIntel. Credit Suisse reinitiated Abbott Laboratories (NYSE:ABT) on Monday, August 10 with “Outperform” rating. Stifel Nicolaus maintained the shares of ABT in report on Thursday, July 20 with “Buy” rating. The rating was initiated by Citigroup on Thursday, August 17 with “Hold”. The firm has “Outperform” rating by RBC Capital Markets given on Friday, January 29. The firm earned “Buy” rating on Tuesday, March 15 by Jefferies. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by RBC Capital Markets on Monday, June 26. The firm earned “Buy” rating on Thursday, August 27 by Wells Fargo. The stock has “Hold” rating by BMO Capital Markets on Thursday, July 20. The stock has “Buy” rating by Deutsche Bank on Friday, July 21. The stock has “Buy” rating by Cowen & Co on Monday, April 17.

Since June 15, 2017, it had 0 buys, and 1 insider sale for $26,482 activity. 552 shares were sold by Watkin Jared, worth $26,482.

Allstate Corp increased Quest Diagnostics Inc (NYSE:DGX) stake by 7,541 shares to 26,323 valued at $2.93 million in 2017Q2. It also upped Ishares Tr (ITOT) stake by 820,419 shares and now owns 1.65M shares. Smucker J M Co (NYSE:SJM) was raised too.

The stock decreased 1.10% or $1.76 on November 8, reaching $158.27. About 673,215 shares traded. Acuity Brands, Inc. (NYSE:AYI) has declined 31.18% since November 8, 2016 and is downtrending. It has underperformed by 47.88% the S&P500.

Acuity Brands, Inc. is a provider of lighting solutions for commercial, institutional, industrial, infrastructure and residential applications throughout North America and other international markets. The company has market cap of $6.66 billion. The Firm operates through North American segment. It has a 21.29 P/E ratio. The Firm offers a portfolio of indoor and outdoor lighting and building management solutions for commercial, institutional, industrial, infrastructure and residential applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 wolcottdaily




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: